Table 2.

Demographic and clinical characteristics for individuals participating in this cohort, stratified by case-control status.

Baseline demographic characteristics and clinical parameters
	HIV +Cases with CKD
	APOL1 -	APOL1 -	APOL1 -	APOL1 -
	0 risk alleles (11)	1 risk alleles (31)	0 + 1 risk alleles (42)	2 risk alleles (40)
Age at enrollment, y	39.8 (35.8–44.8)	46.2 (40.9– 51.1)	44.8 (38.9– 50.8)	44.8 (36.5–51.5)
Female sex, n (%)	63.6	67.7	66.6	62.9
CKD-EPI eGFR, mL/min/1.73 m2	42.7 (20.1–51.2)	36.8 (22.3–56.2)	39.3 (20.6–54.9)	18.6 (11.6–42.3)
UACR, mg/mmol	1.5 (0.5–2.4)	2.79 (0.99–10.7)	2.26 (0.94–6.25)	3.2 (0.7–64.9)
JC virus, %	9	22.5	19	12.5
Log (JC titers)a	2.78	4.4 (3.7–5.5)	4.3 (3.2–5.5)	2.9 (2.3–4.9)
BK virus, %	27.2	32.2	30.9	17.5
Log (BK titers)a	1.27 (1–1.9)	3.8 (2.4–4.6)	3.3 (1.2–4.6)	2.3 (1.8–3)
HIV virus, %	54.5	19.3	28.5	37.5
Log (HIV titers)a	1.6 (1.5–3.6)	3 (1.9–4.2)	2.2 (1.5–4.3)	3.2 (2–4.3)
	HIV+ controls without CKD
	APOL1 -	APOL1 -	APOL1 -	APOL1 -
	0 risk alleles (39)	1 risk alleles (51)	0 + 1 risk alleles (90)	2 risk alleles (27)
Age at enrollment, y	39.2 (33.9–47)	38.9 (34.6–49.9)	39.1 (34.2–49.8)	43.9 (38.2–48.8)
Female sex, n (%)	76.9	72.5	74.4	62.9
CKD-EPI eGFR, mL/min/1.73 m2	117.8 (104.4–131.8)	124.6 (109–130.86)	121.6 (106.6–131.6)	120 (109.5–130.3)
UACR, mg/mmol	0.6 (0.5–1.2)	0.6 (0.4–1)	0.6 (0.4–1)	0.7 (0.5–1)
JC virus, %	17.9	25.5	22.2	7.4
Log (JC titers)a	4.6 (2.6–5.3)	5.1 (3.3–5.8)	4.7 (2.7–5.8)	4.7 (4.2–5.2)
BK virus, %	10.2	31.3	22.2	18.5
Log (BK titers)a	1.5 (1.1–1.6)	2.6 (1.2–3.7)	2 (1.1–3.5)	1 (1–3.1)
HIV virus, %b	15.3	27.4	22.2	51.84
Log (HIV titers)a	2.5 (2.3–2.8)	2.2 (1.5–2.8)	2.2 (1.6–2.9)	3.2 (1.7–4.8)

Data presented as median (25th percentile to 75th percentile) for continuous variables or % for categorical variables.

CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration.

^aData from subjects that have viremia or viruria measured.

^bHIV viremia: more than 20 copies/ml.